Abstract
Objectives Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus with heterogeneous clinical outcomes and limited therapeutic options. Although immune dysregulation is central to LN pathogenesis, the underlying cell-type-specific regulatory mechanisms and their genetic determinants remain poorly characterized.
Methods We generated a single-cell multi-omics atlas of peripheral blood mononuclear cells (PBMCs) from newly diagnosed, minimally treated LN patients by integrating single-cell RNA-seq (scRNA-seq) and single-nucleus ATAC-seq (snATAC-seq) profiles. To elucidate genetically driven regulatory programs in a broaden LN population, we generated a blood expression quantitative trait loci (eQTL) atlas from 99 Chinese LN patients and performed Bayesian colocalization analysis to systematically prioritize putative causal genes for LN. Finally, we investigated how fine-mapped SNPs associated with LN phenotypic manifestations exert regulatory effects within distinct single-cell chromation contexts by leveraging peak-to-gene linkages at single-cell resolution.
Results Our single-cell multi-omic dataset and orthogonal analytical approaches revealed extensive immune remodeling in LN, characterized by amplified innate immune activation and impaired adaptive immune responses, and identified transcription factors (TFs) orchestrating immune regulatory circuits. Bayesian colocalization analysis nominated 14 high-fidelity causal genes for kidney function and 23 for SLE. Integration with fine-mapped GWAS variants highlighted critical cell type convergence across autoimmune disorders and immune-mediated nephropathies, particularly within B cell subsets, where TF-driven programs delineated stage-specific differentiation networks.
Conclusions Together, these analyses reconstruct the regulatory architecture underlying immune dysregulation in LN and connect genetic variation to cell-type-specific regulation, guiding genetically informed therapeutic development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the National Natural Science Foundation of China [32300534, 32270659 to X.S., and 82100765 to T. C.], Basic Research Program of Jiangsu [BK20243061 to Z. L.], the Open Project of Jiangsu Provincial Science and Technology Resources (Clinical Resources) Coordination Service Platform [TC2023006 to X.S.], the Key R&D Program of Zhejiang Province [2024SSYS0021 to X.S.], the Natural Science Foundation of Zhejiang Province [LZ25C060002 to X.S. and LQ24C060001 to J.Z.], the Fundamental Research Funds for the Central Universities [K20250114 to X.S.], and the hundred talents program of Zhejiang University to X.S.; We thank the technical support from the Core Facilities, Liangzhu Laboratory, Zhejiang University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Human Subjects Committee of Jinling Hospital, Nanjing University (Approval No. 2022DZKY-060-01), and conducted according to ethical guidelines, with written informed consent obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
